Join The Discussion

 

Dallas Fed's Fisher, Philadelphia Fed leaders to retire in 2015

WASHINGTON — The outspoken president of the Federal Reserve Bank of Philadelphia will step down in March, shortly before the central bank is expected to raise interest rates for the first time since the recession, the regional bank said Monday.

read more >

RadioShack sees stock jump on investment report

Fort Worth-based RadioShack saw its stock increase as much as 45 percent on Friday as investor Standard General LP said it was continuing talks on new financing for the electronics retailer.

read more >

Fort Worth couple gets in 'Shark Tank,' comes out with deal

A Fort Worth couple who started a business when they couldn’t sleep, were the first entrepreneurs to get a deal on ABC’s Shark Tank in the season premiere on Sept. 26.

read more >

Internal audit says EPA mismanaged Fort Worth project

FORT WORTH, Texas (AP) — An internal audit by the U.S. Environmental Protection Agency reveals the agency mismanaged an experiment using new ways to demolish asbestos-ridden buildings.

read more >

Weatherford's Wild Mushroom to open in Fort Worth's Ridglea Village

Weatherford restaurant staple The Wild Mushroom Steak House & Lounge will be coming to Fort Worth in November, moving into the former site of Ray’s Steakhouse at to 3206 Winthrop Ave. in the Ridglea Village Shopping Center.

read more >

Galderma gains distribution rights in U.S., Canada

Nestle S.A., Switzerland, a shareholder of Fort Worth-based Galderma Laboratories LP, has entered into an agreement with Valeant Pharmaceuticals International Inc. to become the distributor of several products in aesthetic dermatology.
Galderma will gain full rights to commercialize Restylane, Perlane, Emervel, Sculptra and Dysport for use in aesthetic dermatology in the United States and Canada.
Restylane, Perlane and Emervel are manufactured by Galderma and sold by its subsidiaries globally, except in the U.S. and Canada, where Valeant holds the distribution rights under terms of a pre-existing agreement with Medicis, which was acquired by Valeant in 2012. Through this transaction, Galderma will be able to further develop and supply these brands globally.


Galderma is acquiring Sculptra, owned by Valeant, and will commercialize it in the U.S. and Canada and select other markets around the world.
Dysport (branded Azzalure in Europe) is marketed by Galderma for aesthetic dermatology indications in many markets around the world. Valeant holds the distribution rights for the aesthetic dermatology indications under a similar agreement with Ipsen. The transaction will allow Galderma to distribute Dysport in the U.S. and Canada.


“The U.S. and Canada represent more than 50 percent of the fast growing global medical aesthetics market. This move secures Galderma’s continued ability to invest in product innovation, medical education, customer service and consumer awareness,” said Humberto C. Antunes, president and chief executive officer of Galderma worldwide.
This transaction is subject to regulatory clearance and other customary closing conditions. Credit Suisse acted as financial advisers, and Debevoise and Plimpton as legal advisers to Galderma.
In February 2014, Nestle announced that it had entered into an agreement with L’Oreal S.A. under which it will acquire the remaining 50 percent of Galderma owned by L’Oreal. The transaction between Nestle and Valeant is subject to regulatory clearance and certain other conditions, and is expected to close in July.

Betty Dillard
bdillard@bizpress.net
 

< back

Email   email
hide
Arena
What do you think of the new plans for a new Will Rogers arena and changes at the Convention Center?